Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx Group (MDXG) EBITDA: 2011-2025

Historic EBITDA for Mimedx Group (MDXG) over the last 15 years, with Sep 2025 value amounting to $22.2 million.

  • Mimedx Group's EBITDA rose 98.80% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.9 million, marking a year-over-year decrease of 14.91%. This contributed to the annual value of $58.9 million for FY2024, which is 58.60% up from last year.
  • Latest data reveals that Mimedx Group reported EBITDA of $22.2 million as of Q3 2025, which was up 79.39% from $12.4 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx Group's EBITDA peaked at $23.4 million during Q2 2024, and registered a low of -$9.6 million during Q2 2022.
  • In the last 3 years, Mimedx Group's EBITDA had a median value of $11.2 million in 2024 and averaged $12.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 2,250.24% in 2022, then surged by 3,981.76% in 2024.
  • Over the past 5 years, Mimedx Group's EBITDA (Quarterly) stood at $1.3 million in 2021, then surged by 780.23% to $11.3 million in 2022, then skyrocketed by 36.95% to $15.5 million in 2023, then decreased by 28.64% to $11.1 million in 2024, then soared by 98.80% to $22.2 million in 2025.
  • Its EBITDA was $22.2 million in Q3 2025, compared to $12.4 million in Q2 2025 and $8.3 million in Q1 2025.